All In Biotech

Drug Trial Radar · NCT05649748

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

91

Actual

Start

Mar 7, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Treprostinil PalmitilDrug

    Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.

  • PlaceboDrug

    Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by SeverityTime frame: From screening up to last follow up visit (Up to approximately 26 months)

Locations

45 sites in 15 countries. Site status is shown where the registry gives one.

  • USA005

    Jacksonville, Florida

  • USA011

    Tampa, Florida

  • USA006

    Chicago, Illinois

  • USA001

    Chicago, Illinois

  • USA102

    New York, New York

  • USA016

    Dallas, Texas

  • ARG004

    Córdoba, Argentina

  • ARG001

    Córdoba, Argentina

  • ARG009

    Quilmes, Buenos Aires, Argentina

  • ARG006

    Rosario, Santa Fe Province, Argentina

  • ARG007

    San Miguel de Tucumán, Tucumán Province, Argentina

  • AUT001

    Vienna, Austria

  • AUT002

    Linz, Upper Austria, Austria

  • BEL003

    Brussels, Belgium

  • BRA004

    Belo Horizonte, Minas Gerais, Brazil

  • BRA006

    Porto Alegre, Rio Grande do Sul, Brazil

  • BRA002

    Blumenau, Santa Catarina, Brazil

  • DNK001

    Aarhus, Central Jutland, Denmark

  • GER005

    Heidelberg, Baden-Wurttemberg, Germany

  • GER003

    München, Bavaria, Germany

  • GER002

    Lübeck, Schleswig-Holstein, Germany

  • ITA005

    Monza, Italy

  • ITA001

    Palermo, Italy

  • ITA004

    Roma, Italy

  • ITA002

    Pavia, Lombardy, Italy

  • JPN005

    Sapporo, Hokkaido, Japan

  • JPN004

    Sapporo, Hokkaido, Japan

  • JPN007

    Kurume-shi, Hukuoka, Japan

  • JPN006

    Tsukuba, Ibaraki, Japan

  • JPN002

    Okayama, Okayama-ken, Japan

  • JPN003

    Suita-Shi, Osaka, Japan

  • MYS005

    Alor Star, Kedah, Malaysia

  • MYS002

    Kuantan, Pahang, Malaysia

  • MYS004

    Sungai Buloh, Selangor, Malaysia

  • MEX003

    Mexico City, Mexico

  • MEX004

    San Luis Potosí City, Mexico

  • MEX005

    Lomas de Guevara, Jalisco, Mexico

  • MEX001

    Monterrey, Nuevo León, Mexico

  • PHL002

    Makati City, Philippines

  • PHL001

    Quezon City, National Capital Region, Philippines

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.